Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
A

Ratings ESG MSCI

Ratings CSPC Pharmaceutical Group Limited: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Highlights: CSPC Pharmaceutical Group Limited
  • The company is in a robust financial situation considering its net cash and margin position.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses: CSPC Pharmaceutical Group Limited
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The company's earnings releases usually do not meet expectations.

Rating Financials

CSPC Pharmaceutical Group Limited SectorHong Kong

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

CSPC Pharmaceutical Group Limited SectorHong Kong

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

CSPC Pharmaceutical Group Limited SectorHong Kong

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

CSPC Pharmaceutical Group Limited SectorHong Kong

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

CSPC Pharmaceutical Group Limited SectorHong Kong

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
12.66B
A
1,057B
A
625B -
BBB
- -
435B
AA
-
363B
AA
296B
AAA
249B
A
222B
A
209B
A
165B
AA
Average 363.34B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. 1093 Stock
  4. Ratings CSPC Pharmaceutical Group Limited